Autologous Natural Killer Cells in Subjects With Plaque Psoriasis

Status Completed

Clinical Trial Summary

This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis. The primary objective of this study is to investigate the safety and tolerability of four infusions of "SNK01" in subjects with plaque psoriasis. Secondary objective is preliminary efficacy of "SNK01" in subjects with plaque psoriasis.

Clinical Trial Description

Nine (9) subjects, male or female, aged 18 years or older will be enrolled in the study, all of whom will receive "SNK01" without placebo control. There are three (3) subjects in each of the three (3) cohorts. The SNK01 study product will be administered at the following doses using dose escalating rules: Cohort 1 will receive 4 weekly infusions of 1 billion cells, Cohort 2 will receive 4 weekly infusions of 2 billion cells, and Cohort 3 will receive 4 weekly infusions of 4 billion cells. Length of participation, per subject, is approximately 12 weeks. The primary endpoint for safety is dose-limiting toxicity (DLT) which is defined as TEAE of grade ≥ 3 considered related to SNK01. Secondary safety endpoints include other adverse events (graded according to National Cancer Institute's Common Toxicity Criteria for Adverse Events [NCI-CTCAE v 5.0]), vital sign measurements, clinical laboratory tests and physical examination. Preliminary efficacy will be measured by Psoriasis Area Severity Index (PASI) and by the Physician's Global Assessment (PGA. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03894579
Study type	Interventional
Source	NKMax America, Inc.
Contact
Status	Completed
Phase	Phase 1
Start date	July 18, 2019
Completion date	December 3, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01194219` - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis	Phase 3
Recruiting	`NCT06030076` - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed	`NCT04263610` - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy	Phase 4
Completed	`NCT02601469` - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05600036` - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis	Phase 2
Completed	`NCT05375955` - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.	Phase 2
Completed	`NCT03614078` - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Not yet recruiting	`NCT05036889` - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.	N/A
Completed	`NCT04603027` - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis	Phase 2
Completed	`NCT03638258` - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis	Phase 2
Completed	`NCT02881346` - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting	`NCT02611349` - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT02251678` - Evaluate the Effect of Elimune Capsules	Phase 1
Completed	`NCT01987843` - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 2
Terminated	`NCT01708629` - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects	Phase 3
Completed	`NCT01230138` - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis	Phase 2
Withdrawn	`NCT00747032` - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis	Phase 3
Completed	`NCT00581100` - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis	Phase 4
Suspended	`NCT01228656` - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate	Phase 2
Completed	`NCT00540618` - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis	Phase 2